Phesgo and Tecentriq Performance and Approvals

Immunology: Actemra COVID-19 sales declining and Esbriet LOE Xolair autoinjector approval and Ph III food allergy readout expected in 2023 Q1 updates CHFM • YoY CER growth Roche Ph III (REGENCY) Gazyva in LN fully recruited; read out expected in 2024 ⚫ Ph III (INShore) Gazyva in PNS initiated Actemra (-12%) 2,500 +9% -5% 2,000 -2% • COVID-19 related sales declining -15% • 1,500 Shift from IV to SC ongoing, SC share at ~60% Esbriet (-69%) 1,000 500 0 Q1 20 Q121 Q122 Q123 Rituxan/MabThera (RA) Actemra SC Actemra IV Xolair ■CellCept Esbriet Pulmozyme Other • Generic competition in US and EU Xolair (+5%) • Market leader in asthma biologics and strong growth in CSU Outlook 2023 . US approval of Xolair autoinjector expected • Ph III (OUTMATCH) in food allergy read out expected • Ph III (IMAGINATION) ASO factor B in IgAN to be initiated 26 CER=Constant Exchange Rates; LOE-loss of exclusivity; RA=rheumatoid arthritis; IV-intravenous; SC=subcutaneous; LN-lupus nephritis; CSU-chronic spontaneous urticaria; ASO=antisense oligonucleotide; IgAN-immunoglobulin A nephropathy; PNS=pediatric nephrotic syndrome

View entire presentation